Tele: 561.316.3330
Breaking Medical Device News

Wednesday, October 20, 2021

MEDICAL DEVICE NEWS MAGAZINE

A DIGITAL PUBLICATION FOR THE PRACTICING MEDICAL SPECIALIST, INDUSTRY EXECUTIVE AND INVESTOR
HomeNativisNativis Appoints Dr. Donna Morgan Murray as Chief Regulatory Officer

Nativis Appoints Dr. Donna Morgan Murray as Chief Regulatory Officer


Chris Rivera, Chief Executive Officer of Nativis notes, “We are very excited to welcome Dr. Donna Morgan Murray as Chief Regulatory Officer to Nativis. Dr. Murray’s extensive professional accomplishments and medical background will provide Nativis with a broad range of experience in worldwide regulatory policy, feasibility and strategy.”  Rivera concluded, “As we develop our technology for the treatment of cancer and other serious diseases, it is critical to consider the regulatory pathway for the Voyager system and develop a comprehensive strategy that will bring us towards regulatory approval.”

Nativis Inc., a clinical stage, bio-electronic life science company developing non-invasive, safe and highly effective treatments for cancers and other serious diseases, announced that Dr. Donna Morgan Murray has been appointed as Chief Regulatory Officer, effective immediately.

Murray is a seasoned healthcare professional, author of more than 60 publications in peer-referenced journals, and has served on the board of non-profits and other organizations. Most recently the Head of Global Quality & Regulatory Compliance at Bristol-Meyers Squibb, Murray has held that role since 2014. Prior to that, she was the President of ZymoGenetics Inc., a biotechnology company that discovers, develops, and manufactures protein therapeutics at Bristol-Meyers Squibb. Over the past 20 years, Murray has led and directed regulatory strategy and operations for Bristol-Myers Squibb, CuraGen Corporation, and Procter & Gamble Pharmaceuticals. Murray began her professional career in 1984 as a staff scientist in the Anti-Infective Research Department with Norwich Eaton Pharmaceuticals, Inc., a Procter & Gamble Company.

Murray holds a PhD in Immunology from The University of Texas Health Science Center at Houston, where she conducted research in infectious disease & clinical microbiology. Outside of her professional work, she serves as an officer and member of the board of K9 Crime Stoppers Inc. and was the Chief Operating Officer for Independence Guide Dogs.

Chris Rivera, Chief Executive Officer of Nativis notes, “We are very excited to welcome Dr. Donna Morgan Murray as Chief Regulatory Officer to Nativis. Dr. Murray’s extensive professional accomplishments and medical background will provide Nativis with a broad range of experience in worldwide regulatory policy, feasibility and strategy.”  Rivera concluded, “As we develop our technology for the treatment of cancer and other serious diseases, it is critical to consider the regulatory pathway for the Voyager system and develop a comprehensive strategy that will bring us towards regulatory approval.”

Murray added, “I am very pleased to join Nativis as the Chief Regulatory Officer and look forward to applying my experience in the biopharmaceutical industry toward developing a strong regulatory strategy for the Company’s ulRFE™ technology. I look forward to working to ensure that Nativis is well prepared to meet regulatory requirements and milestones for its unique technology platform and to streamline the regulatory process and help rapidly move forward with the Voyager system.”

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Stay Connected

spot_img

Don't Miss

Contraline Closes $10.7 Million Series A Financing to Become a Clinical Stage Company

This infusion of capital will support the initiation of a first-in-human trial of ADAM™, the world’s first hydrogel implant designed to provide long-lasting, non-permanent contraception for men.

Adam S. Epstein New CEO of AliMed, Inc.

In his prior role as Chief Commercial Officer, Epstein directed all customer-facing, demand generation and product development activities. Under his new leadership, AliMed will continue to build a robust portfolio of contracted positions with major, national GPO’s, IDN’s, and Distribution partners to drive sales growth.

Tony Collins Appointed CFO of Xenter

“Xenter is building a platform for medical innovations that is transformational. The only way we can achieve our objectives is if we have great leaders like Tony Collins leading our company,” stated Richard J. Linder, Founder, Chairman & CEO of Xenter, Inc. “Tony brings incredible depth and experience to his new role as Chief Financial Officer.

Scott Sexton Appointed President at FIGUR8

"Scott brings to FIGUR8 30 years of workers' compensation, casualty, disability, and commercial health experience, most recently serving as a market leader for CorVel's national carrier practice sales team," said Nan-Wei Gong, CEO, and co-founder of FIGUR8.

Insulet Announces Board of Director Changes with Appointment of Luciana Borio, M.D. and Retirement of Sally W. Crawford

Luciana Borio MD is a respected physician with vast experience in advancing major regulatory and policy agendas for the United States.

Ganymed Robotics Awarded a €2.5M Grant from the EC through the EIC Accelerator Program

Ganymed Robotics is developing a radically new approach to surgical robotics by combining computer vision, a branch of artificial intelligence, and mechatronics.

By using this website you agree to accept Medical Device News Magazine Privacy Policy